Ra Pharmaceuticals (RARX) PT Raised to $42.00

Ra Pharmaceuticals (NASDAQ:RARX) had its target price increased by SunTrust Banks to $42.00 in a research report issued to clients and investors on Friday, The Fly reports. The firm currently has a “buy” rating on the stock. SunTrust Banks’ target price suggests a potential upside of 76.10% from the company’s current price.

Several other research firms have also weighed in on RARX. Raymond James set a $49.00 price objective on shares of Ra Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, April 10th. ValuEngine raised shares of Ra Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Monday, February 4th. Guggenheim started coverage on shares of Ra Pharmaceuticals in a report on Friday, February 22nd. They set a “buy” rating and a $48.00 price objective for the company. BMO Capital Markets set a $33.00 price objective on shares of Ra Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, March 8th. Finally, BidaskClub lowered shares of Ra Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Wednesday, February 20th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $38.00.

NASDAQ RARX opened at $23.85 on Friday. The company has a market cap of $1.02 billion, a PE ratio of -11.58 and a beta of 0.79. The company has a debt-to-equity ratio of 0.02, a current ratio of 20.10 and a quick ratio of 20.10. Ra Pharmaceuticals has a 1-year low of $5.86 and a 1-year high of $27.68.

Ra Pharmaceuticals (NASDAQ:RARX) last posted its quarterly earnings data on Thursday, May 9th. The company reported ($0.45) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.47) by $0.02. Equities analysts predict that Ra Pharmaceuticals will post -1.99 earnings per share for the current year.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Citigroup Inc. grew its holdings in Ra Pharmaceuticals by 18.6% during the 1st quarter. Citigroup Inc. now owns 3,709 shares of the company’s stock worth $84,000 after acquiring an additional 582 shares during the period. JPMorgan Chase & Co. grew its holdings in Ra Pharmaceuticals by 0.3% during the 1st quarter. JPMorgan Chase & Co. now owns 239,269 shares of the company’s stock worth $5,360,000 after acquiring an additional 678 shares during the period. Legal & General Group Plc grew its holdings in Ra Pharmaceuticals by 57.7% during the 4th quarter. Legal & General Group Plc now owns 3,063 shares of the company’s stock worth $56,000 after acquiring an additional 1,121 shares during the period. ClariVest Asset Management LLC grew its holdings in Ra Pharmaceuticals by 6.0% during the 1st quarter. ClariVest Asset Management LLC now owns 21,300 shares of the company’s stock worth $477,000 after acquiring an additional 1,200 shares during the period. Finally, Group One Trading L.P. acquired a new stake in Ra Pharmaceuticals during the 1st quarter worth $34,000. 90.73% of the stock is owned by hedge funds and other institutional investors.

About Ra Pharmaceuticals

Ra Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules.

See Also: What is the formula for the cash asset ratio?

The Fly

Analyst Recommendations for Ra Pharmaceuticals (NASDAQ:RARX)

Receive News & Ratings for Ra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.